Skip to main content


Table 3 Correlations between biomarkers expressed as P values (Chi square test)

From: Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

  MET overexpression p-MET overexpression HGF overexpression MET amplification
MET overexpression   0.013 0.517 0.004
p-MET overexpression 0.013   0.001 0.047
HGF overexpression 0.517 0.001   0.786
MET amplification 0.004 0.047 0.786  
  1. Expression levels as determined by IHC. Results include all 57 patients